Precise neurological treatments with AI administration will offer “Safe treatments to more”

We preemptively predict what patients are at risk of developing complications if they are given a treatment, based on data available at baseline.

We determine whether a patient cohort can be divided into smaller groups for more accurate follow-up and treatment

Finding patients that are likely to have a high response to treatments is key for pharma arguing the cost-benefits of the treatment.

What problem are we solving?

Over 55M people worldwide live with dementia, and healthcare systems are unprepared for the growing patient surge.

New Alzheimer's therapies face response and side-effect tradeoffs, yet over 100 treatments in development offer promise.

Pharmaceuticals must demonstrate a cost-benefit superior to existing therapies to justify pricing and reimbursement.